Novartis chases Roche's oncology crown
This article was originally published in Scrip
Novartis, which has grown rapidly since the start of the decade to become the second biggest pharmaceutical company in the oncology arena in terms of sales, hopes to catch up over time to its cross-town rival Roche, it said during a recent oncology and pipeline update for investors.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.